IP Practice: Sidley Austin
The number of Hatch-Waxman Act-related lawsuits will likely drop over the next five years, but generic companies may start to challenge biotechnology patents, said the co-head of Sidley Austin's intellectual property...To view the full article, register now.
Already a subscriber? Click here to view full article